Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Trends Microbiol. 2012 Nov;20(11):532-9. doi: 10.1016/j.tim.2012.08.011. Epub 2012 Sep 13.
Attempts to formulate a protective HIV-1 vaccine through classic vaccine design strategies have not been successful. Elicitation of HIV-1-specific broadly neutralizing antibodies (bnAbs) at high titers that are present before exposure might be required to achieve protection. Recently, the application of new technologies has facilitated the study of clonal lineages of HIV-1 envelope (Env) antibodies, which have provided insights into HIV-1 antibody development during infection and upon vaccination. Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design.
通过经典疫苗设计策略来尝试制定一种保护性 HIV-1 疫苗尚未成功。在接触前可能需要诱导出高滴度的 HIV-1 特异性广泛中和抗体（bnAbs）才能实现保护。最近，新技术的应用促进了 HIV-1 包膜 (Env) 抗体克隆谱系的研究，这些研究提供了对感染和接种疫苗期间 HIV-1 抗体发育的深入了解。目前正在制定分析感染和候选疫苗诱导的抗体、它们的基因使用以及它们的成熟途径的策略，以便利用这些信息尝试指导合理的疫苗设计。
